Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation (Nasdaq: LFVN) is a Delaware-incorporated health and wellness company that focuses on nutrigenomics and cellular activation, and its SEC filings provide detailed insight into its operations, governance, and financial performance. As a public company, LifeVantage files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, among other documents.
Through these filings, investors can review information about LifeVantage’s activator-based product portfolio, which includes the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, P84, AXIO nootropic energy drink mixes, activation-supporting nutrients, the TrueScience skin and hair care line, and Petandim. The filings also describe the company’s direct selling model, under which independent Consultants sell products to Customers and share the business opportunity with entrepreneurs.
Current reports on Form 8-K document material events such as financial results announcements, executive officer changes, and other significant corporate developments. Definitive proxy statements (DEF 14A) provide detail on board composition, executive compensation, equity incentive plans like the 2017 Long-Term Incentive Plan, and matters submitted to stockholder votes, including director elections, say-on-pay proposals, and auditor ratification. Voting results for these proposals are also reported in 8-K filings.
On this page, LifeVantage filings are updated as they are made available through the EDGAR system. AI-powered tools summarize key sections of lengthy documents, helping readers understand topics such as revenue trends, non-GAAP measures like adjusted EBITDA and adjusted earnings per share, stock-based compensation plans, and governance structures without reading every line. Users can also review disclosures related to dividends, share repurchases, and risk factors referenced in the company’s periodic reports.
For those researching LFVN, this filings archive offers a structured view of LifeVantage’s regulatory history, financial reporting, and corporate decision-making, with AI-generated highlights to make complex filings more accessible.
LifeVantage (LFVN) director Michael A. Beindorff reported insider activity on Form 4. On 11/06/2025, he received 13,531 shares under the outside director compensation program, scheduled to vest on November 6, 2026; the price shown is $7.76, equal to the weighted average closing price over the prior ten trading days. On 11/07/2025, he sold 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust), with a portion sold to cover taxes from a restricted stock vesting. Following these transactions, holdings include 35,389 shares direct, 56,413 shares indirect via trust, 126 shares held by spouse as custodian for minor children, and 5,500 shares held by spouse.
LifeVantage (LFVN) director Dayton Judd reported an equity award on a Form 4. On 11/06/2025, he was granted 13,531 shares of common stock under the company’s outside director compensation program. These shares will vest in a single installment on November 6, 2026.
The filing lists a price of $7.76, described as the weighted average closing price for the ten trading days ending the day before the grant date. Following the transaction, Judd beneficially owns 47,162 shares directly and 749,325 shares indirectly through Sudbury Capital Fund, LP.
LifeVantage (LFVN) reported a routine insider equity award. Director Darwin Lewis acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The price reported was $7.76, defined as the weighted average closing price over the ten trading days ending the day before the grant.
These shares will vest in a single installment on November 6, 2026, contingent on continuous service. Following the grant, Lewis beneficially owns 130,748 shares, held directly.
LifeVantage Corporation filed a current report to note that it issued a press release on November 4, 2025 announcing its financial results for the three months ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference for full details of the quarterly performance.
LifeVantage (LFVN) reported Q1 FY2026 results for the quarter ended September 30, 2025. Revenue was $47.6 million, up slightly from $47.2 million a year ago, as the MindBody GLP-1 System offset lower sales of Protandim and TrueScience. Gross profit was $37.8 million, a 79.5% margin.
Net income rose to $2.2 million from $1.8 million, with diluted EPS of $0.17 versus $0.14. The U.S. delivered $35.2 million in revenue, essentially flat, while Japan increased 3.5% to $6.2 million. Active Independent Consultants grew to 48,000, but total Active Customers declined to 73,000, bringing total Active Accounts to 121,000.
Cash and equivalents were $13.1 million, down from $20.2 million at June 30, 2025, reflecting $2.3 million used in operating activities, $0.6 million in cash dividends ($0.045 per share), and $0.6 million of share repurchases (44,000 shares). The company’s $5.0 million revolving credit facility had no balance outstanding; an amendment now permits use for acquisitions. On October 1, 2025, LifeVantage closed the acquisition of critical assets of LoveBiome, with purchase accounting pending.
Shares outstanding were 12,701,187 as of November 3, 2025.
LifeVantage (LFVN) filed a Form 3/A amendment for officer Todd Thompson, Chief Information Officer, updating his beneficial holdings. The filing corrects common stock ownership to 51,330 shares and adds 16,491 performance RSUs granted on August 26, 2025. The original reported 40,336 shares and omitted this PRSU grant.
It also lists 3,750 PRSUs granted on December 23, 2024. Vesting for the 2024 grant: 50% on August 31, 2025; 30% on August 31, 2026; 20% on August 31, 2027, subject to performance and continued service. The 2025 grant vests 34% on September 10, 2026; 33% on September 10, 2027; and 33% on September 10, 2028. The amendment adds Exhibit 24, Power of Attorney.
Lifevantage (LFVN) disclosed the initial insider holdings of its Chief Information Officer. The officer directly owns 40,336 shares of common stock and holds 3,750 performance restricted stock units (PRSUs) at target eligibility.
The PRSUs were granted on December 23, 2024 and vest only upon achievement of specified financial performance criteria: 50% vested on August 31, 2025, with 30% scheduled for August 31, 2026 and 20% on August 31, 2027. Upon maximum performance achievement, up to 200% of the target number of units may be earned.
Kristen Cunningham, Chief Sales Officer and director at Lifevantage Corp (LFVN), reported an insider sale on 10/01/2025. The filing shows she sold 1,720 shares of Lifevantage common stock at a price of $9.56 per share, leaving her with 136,986 shares owned directly. The Form 4 was signed by a power of attorney on 10/03/2025. This report discloses a routine officer sale and the resulting post-transaction ownership.
Alissa Neufeld, who identifies her role as General Counsel of Lifevantage Corp (LFVN), reported a sale of 1,283 shares of the company's common stock on 10/01/2025 at a reported price of $9.56 per share. After the transaction the filing shows Ms. Neufeld beneficially owns 116,977 shares. The Form 4 is signed and dated 10/03/2025, indicating timely disclosure under Section 16 reporting requirements.
On 10/01/2025 Steven R. Fife, who is listed as President and CEO and a Director of Lifevantage Corp (LFVN), reported a sale of 8,181 shares of the company's common stock at a price of $9.56 per share. After the reported transaction, Mr. Fife's beneficial ownership is listed as 752,820 shares. The Form 4 was signed by a power of attorney on 10/03/2025.